Hybrid integrated molecular analysis (HIMAS) for point-of-care diagnostics
Hybrid integrated molecular analysis (HIMAS) for point-of-care diagnostics
批准号:
8839984
负责人:
Holger Schmidt
金额:
$50.23万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-01 至 2017-05-31
关键词:
Anthrax diseaseAntigensAreaBiologicalBiomedical ResearchCategoriesClinicalCommunicable DiseasesComplexDecision MakingDetectionDevicesDiagnosisDiagnosticDifferential DiagnosisDisease ManagementDisease OutbreaksEarly DiagnosisEnvironmentEpidemicFluorescenceFoundationsGeneticGenetic screening methodGlassGoalsHealthHumanHybridsJunin virusMeasuresMedicineMicrofluidicsMissionMolecularMolecular AnalysisMonitorNational Institute of Allergy and Infectious DiseaseNucleic AcidsOpticsOutcomePatient IsolationPatientsPhasePoint-of-Care SystemsPolymerase Chain ReactionPopulationPreparationPrincipal InvestigatorProcessPublic HealthResearchResearch ActivityResearch InstituteResourcesRespiratory Tract InfectionsSamplingSiliconSolutionsSpeedStructureSystemTechnologyTestingTexasUnited States National Institutes of HealthValidationViralViral Hemorrhagic FeversViral Load resultVirusWhole BloodWorkbasebiodefenseclinically relevantcombinatorialdigitaleffective therapyhemorrhagic fever virushigh riskinfectious disease treatmentinnovationinstrumentmortalitymultiplex detectionnovel strategiesnucleic acid detectionpathogenpoint of carepoint-of-care diagnosticsprogramsprototyperesponsescreeningviral detectionweapons
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Principal Investigator/Program Director: Schmidt, Holger
Project Summary
Highly infectious diseases originating from bacterial (e,g, anthrax) or viral (e.g. Ebola)
pathogens with high mortality rates pose high risks, including epidemic outbreaks and hostile
acts using these pathogens as biological weapons. The ability to detect and respond rapidly at
the "point of care" is essential for dealing with these threats. Despite increased research activity,
there is currently no established point-of-care system for these pathogens due to the
shortcomings of the current detection approaches, including lack of speed (culture), lack of
accuracy (antigen tests), and lack of simplicity (polymerase chain reaction (PCR), in large part
due to the need to amplify the genetic target material). Our long-term goal is to develop point-of-
care biomedical devices using optofluidics - the combination of integrated optics and
microfluidics on a single chip-scale system. The objective of this application is to demonstrate
and validate a Hybrid, Integrated Molecular Analysis System (HIMAS) that is suitable for
differential point-of-care diagnosis of category A pathogens. Our central hypothesis is that this
can be accomplished by combining two powerful microfluidic and optical technologies that are
optimized for sample processing and amplification-free detection in separate chip layers.
During the initial R21 phase, our objectives will be accomplished by the following specific aims:
(1) Introduce a new spectral target multiplexing approach using interferometric waveguide
structures; (2) Introduce a new hybrid optofluidic system composed of a glass microfluidic layer
and a silicon optical layer; (3) Validate the platform for differential diagnostics of hemorrhagic
fever viruses using clinical samples. In a subsequent R33 phase, we will build on these
innovations by developing a portable prototype system that can rapidly distinguish between 14
weaponizable hemorrhagic fever viruses without the need for target amplification, starting from
a whole blood patient sample. The innovative contributions of the proposed approach are: (i)
interferometric excitation using multi-mode interferometer (MMI) waveguides for spectral,
spatial, and combinatorial target multiplexing; (ii) introduction of a new planar optofluidic system
with layers optimized individually for sample processing and amplification-free nucleic acid
analysis. The proposed work is significant because it overcomes the critical barriers to
developing a point-of-care system for PCR-free, differential diagnostics of biodefense
pathogens and other viral and bacterial threats to human health.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nanopore-based multi-target analysis of Zika virus infection
-
批准号:10181749
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2019
-
负责人:Holger Schmidt
-
依托单位:
Nanopore-based multi-target analysis of Zika virus infection
-
批准号:9815879
-
项目类别:
-
资助金额:$61.22万
-
财政年份:2019
-
负责人:Holger Schmidt
-
依托单位:
Nanopore-based multi-target analysis of Zika virus infection
-
批准号:10395953
-
项目类别:
-
资助金额:$56.71万
-
财政年份:2019
-
负责人:Holger Schmidt
-
依托单位:
Hybrid integrated molecular analysis (HIMAS) for point-of-care diagnostics
-
批准号:8301986
-
项目类别:
-
资助金额:$25.78万
-
财政年份:2012
-
负责人:Holger Schmidt
-
依托单位:
Hybrid integrated molecular analysis (HIMAS) for point-of-care diagnostics
-
批准号:8468115
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2012
-
负责人:Holger Schmidt
-
依托单位:
Integrated Optical Particle Trap for Biomolecule Analysis and Manipulation
-
批准号:7826787
-
项目类别:
-
资助金额:$18.02万
-
财政年份:2009
-
负责人:Holger Schmidt
-
依托单位:
Integrated Optical Particle Trap for Biomolecule Analysis and Manipulation
-
批准号:7510248
-
项目类别:
-
资助金额:$21.87万
-
财政年份:2009
-
负责人:Holger Schmidt
-
依托单位:
Single biomolecule sensors using integrated optical waveguides with liquid cores
-
批准号:7564758
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2006
-
负责人:Holger Schmidt
-
依托单位:
Single biomolecule sensors using integrated optical waveguides with liquid cores
-
批准号:7076740
-
项目类别:
-
资助金额:$40.16万
-
财政年份:2006
-
负责人:Holger Schmidt
-
依托单位:
Single biomolecule sensors using integrated optical waveguides with liquid cores
-
批准号:7201667
-
项目类别:
-
资助金额:$40.3万
-
财政年份:2006
-
负责人:Holger Schmidt
-
依托单位:
Single biomolecule sensors using integrated optical waveguides with liquid cores
-
批准号:7342896
-
项目类别:
-
资助金额:$38.69万
-
财政年份:2006
-
负责人:Holger Schmidt
-
依托单位:
Integrated Optical Waveguide Sensors
-
批准号:6756720
-
项目类别:
-
资助金额:$18.37万
-
财政年份:2004
-
负责人:Holger Schmidt
-
依托单位:
Integrated Optical Waveguide Sensors
-
批准号:6856477
-
项目类别:
-
资助金额:$14.69万
-
财政年份:2004
-
负责人:Holger Schmidt
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: